Introduction

The respiratory market will continue to experience strong growth for the next 6 years, driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark studies. Despite patent expiries of three leading products, from 2010, the market will avoid a collapse like the one seen for oral antihistamines.

Scope

*Indication based forecasts for asthma/COPD products and significant pipeline drugs

*Assessment of country-specific drivers and resistors likely to impact the market

*Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates

*Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance

Highlights

Global asthma/COPD sales should grow to over $30 billion by 2012 and remain flat thereafter, with inhaled corticosteroid/long-acting bronchodilator combinations set to remain the leading class by value throughout. Anticholinergics will experience the strongest growth, particularly in COPD, to become the second-best selling class.

GSK's Super Advair should become the top-selling brand in the seven major markets in 2015 if the company manages to switch Seretide/Advair prescriptions successfully before Seretide's US patent expires.

The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2 agonists (SABAs), more than doubling its size. The main beneficiary will be Sepracor's Xopenex MDI.

Reasons to Purchase

*Identify key opportunities and threats that will impact the use and uptake of new and existing products

*Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds

*Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

Commercial Insight: Asthma/COPD - ICS/LABA combinations continue to dominate